ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

Geneva, Switzerland – November 30, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that, following a comprehensive assessment of the company's financial position, the Board of Directors has opted to seek a moratorium from the competent court in Geneva, Switzerland. The moratorium, if granted, will provide essential protection, enabling the company to focus on negotiations and conclusions of deals that could significantly impact its trajectory.